The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|May 3, 2021
Rheumatoid Arthritis Quiz: RA and Heart Attack
Author(s)Ingrid Torjesen
Rheumatoid arthritis increases cardiovascular risk and the risk of heart attack, but by how much and what impact does treatment have on that risk? Test your knowledge in this quiz.
Advertisement
Compared to the general population, by how much is the risk of cardiovascular disease increased in people with rheumatoid arthritis?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement